Endocrine Abstracts

Introduction: LADA exhibits characteristics of both type 1 diabetes mellitus (DM) and type 2 DM. Patients with LADA usually have some components of metabolic syndrome. GLP-1 agonists have been widely used in type 2 DM. GLP-1 agonist therapies have shown some promising glucose lowering effect in T1DM. Almost no information is available on glucagon and incretin secretion in patients with LADA as well as effects on glucose and C-peptide levels.Case report: ...

Background and aims: Hypoglycemia can be a risk factor for adverse cardiovascular and cerebrovascular events. However, changes in platelets and coagulation hemostasis during hypoglycemia have not been extensively studied. The aim of this study was to assess the impact of insulin-induced hypoglycemia on the platelet activity, endothelial dysfunction and the physiological anticoagulant level in patients with DM1.Research design and methods: We studied seve...

Introduction: Obesity and diabetes mellitus type 2 (T2DM) are considered as one of the major risk factor for coronary heart disease (CHD) development, but the mechanisms beyond this relationship still need to be clarified. miRNAs are supposed to be involved in regulatory mechanisms in this relationship.Aim: To determine miRNAs expression in patients with obesity and T2DM.Methods: MiRNAs were detected in peripheral blood of 43 patie...

Introduction: Obesity and type 2 diabetes mellitus (T2DM) are associated with cardiovascular diseases (CVD). Fibrotic changes in obesity include several molecular processes, including activation of Transforming growth factor β (TGF-β). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM.Aim: To determine TGF-β and FGF-2...

Aim of the study: To analyze the dynamics and levels of incretins and neuropeptides secretion in patients with CD and acromegaly and therefore to specify the pathogenesis of carbohydrate metabolism disturbances.Methods: Forty-two patients with Cushing disease and acromegaly were included into the study. All patients were newly diagnosed with Cushing disease and acromegaly. Oral glucose tolerance test (OGTT), during which glucose, glucagon, glucagon like ...

Background: Patients with type 1 diabetes have a significantly higher risk of coronary events, as well as diseases of the cardiovascular system.Purpose of the study – to show the relationship between metabolic, structural, and functional parameters of the cardiovascular system in young patients with DM1.Methods: The study included 60 patients without CVD: 40 patients with DM1 and 20 patients without DM1, the groups were comparable in age, sex, AMT, ...

Background and aims: Hyperglycemia can be a risk factor for adverse cardiovascular and cerebrovascular events. However, changes in platelets and coagulation hemostasis during hyperglycemia have not been extensively studied. The aim of this study was to assess the impact of level of fasting plasma glucose, HbA1c on the platelet activity, the physiological anticoagulant activity and fibrinolysis in patients with Diabetes Mellitus type 1 (DM1).Ma...

Background and aims: In 2005, experts from the IDF assigned the risk of developing coronary heart disease in patients with type 1 diabetes mellitus (DM1) at age of 30 and over or patients with DM1 with kidney damage equal to the patients with type 2 diabetes mellitus. The need for a non-invasive preclinical marker for identifying patients with the increased risk of cardiovascular disease is obvious. The assessment of arterial stiffness can play a role of such marker. The aim o...

Aim: To estimate the efficacy of structured lifestyle modification program on clinical and metabolic status in overweight/obese patients with type 2 diabetes (T2DM).Materials and methods: The program was implemented in 2 centers (Moscow, Kazan) and 130 participants were recruited (100-active group, 30-control group). The patients’ characteristics in active group: mean age was 54.6±10.2 years, diabetes duration 6.6±5.6 years, BMI 34.4±...

Background and aims: To evaluate the level of tubular and glomerular biomarkers of kidney injury as potential nephroprorotective effects of GLP-1R agonist (liraglutide) addition in type 1 diabetic patients compared to standard insulin therapy.Materials and methods: 12 T1DM patients with normo-(AER <20 mg/l, n=7) and microalbuminuria (AER<199 mg/l, n=5) with liraglutide 1.2 mg as add on to insulin for 6 month and 12 patients with...